All In Biotech

Drug Trial Radar · NCT07867171

A Study to Investigate the Effects of Moderate or Severe Renal Impairment (RI) on Velzatinib

A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of Velzatinib in Participants With Moderate or Severe Renal Impairment Compared to Healthy Participants

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Oct 23, 2026

Primary completion

Sep 9, 2027

Study completion Sep 9, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Oct 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study evaluates the effect of moderate and severe renal impairment on the pharmacokinetics (PK) of velzatinib compared with normal renal function.

Conditions

  • Healthy Participants
  • Gastrointestinal Neoplasms

Interventions

  • VelzatinibDrug

    Velzatinib will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed plasma concentration (Cmax)Time frame: Up to 936 hours
  2. Area under the concentration-time curve from time zero extrapolated to infinity (AUC[0-inf])Time frame: Up to 936 hours
  3. Maximum plasma unbound concentration (Cmax,u)Time frame: Up to 936 hours
  4. Area under the unbound plasma concentration-time curve extrapolated to infinity (AUC[0-inf],u)Time frame: Up to 936 hours
  5. Renal clearance (CLr)Time frame: Up to Day 3

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.